What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


Aug. 23

Weekly Gain

Net 1 Ueps Technologies (NASDAQ:UEPS)



Horizon Pharma (NASDAQ:HZNP)



Best Buy (NYSE:BBY)



Tesla Motors (NASDAQ:TSLA)



Questcor Pharmaceuticals (UNKNOWN:QCOR.DL)



Source: Barron's.

Let's start with Net 1 Ueps Technologies. You don't often see a stock move 50% higher on earnings, but Net 1 came through with a blowout quarter. The electronic-transaction processor saw revenue climb 25% to $118 million, with fundamental earnings of $0.28 a share. Analysts were holding out for net income of just $0.19 a share on $114 million in revenue.

It gets better. Net 1 expects to earn at least $1.50 a share this new fiscal year, well ahead of the $1.16 Wall Street was targeting. Even after this week's 50% pop, the shares are fetching just seven times projected earnings.

Horizon Pharma moved higher after settling pending patent litigation with Par Pharmaceuticals involving DUEXIS tablets that combine ibuprofen and famotidine. Horizon has six Orange Book patents covering DUEXIS, and the settlement will push Par's entry with a generic version of the tablets until as late as 2023.

Best Buy moved higher after landing well ahead of the prognosticators in its latest quarter. The chain of consumer-electronics superstores managed to grow its adjusted earnings to $0.32 a share from the $0.26 it posted a year earlier. Wall Street was bracing for a sharp drop in profitability. Sales slipped 1% for the quarter, but that was also well ahead of where analysts were modeling the retailer's performance.

Tesla continues to put the pedal to the metal. The electric-car maker's Model S scored a record 5.4 stars in the National Highway Traffic Safety Administration's vehicle safety rating. The stock is up a scintillating 379% so far this year!

Finally, Questcor moved higher after an analyst upgrade. Bank of America/Merrill Lynch moved the stock from "neutral" to "buy," encouraged by the growth potential of the controversially expensive Acthar gel. The firm's price target on the shares is now $80.